Novartis Submits Cosentyx for PMR Review in US, EU, and Japan After Phase III REPLENISH Data

Concurrent regulatory submissions in three major markets signal that Novartis is moving secukinumab toward a new approved indication, and for manufacturing and supply chain teams, that trajectory warrants early attention. The company has filed Cosentyx (secukinumab) for polymyalgia rheumatica (PMR) with health authorities in the US, EU, and Japan, with additional country submissions expected throughout 2026, following Phase III REPLENISH data published in the New England Journal of Medicine on June 3, 2026.

The REPLENISH trial met all primary and secondary endpoints across both the 300 mg and 150 mg secukinumab arms at week 52. Sustained remission was achieved in 41.2% of patients on 300 mg and 40.6% on 150 mg, compared with 20.4% on placebo, roughly double the remission rate. Mean adjusted annual cumulative glucocorticoid dose was 1,604 mg and 1,683 mg in the active arms versus 2,093 mg for placebo, with both differences statistically significant (p < 0.001 and p = 0.0015, respectively). No new safety signals were identified, consistent with the established Cosentyx profile across its existing indications.

For regulatory affairs leads, the simultaneous tri-market filing compresses the review timeline management window. Each jurisdiction, FDA under 21 CFR, EMA, and PMDA, will apply its own dossier requirements and inspection readiness expectations. Teams managing CMC sections should anticipate questions around process validation and comparability if any manufacturing changes have occurred since prior BLA or MAA submissions for existing Cosentyx indications.

The supply-chain read is direct: a biologic already approved across six indications in adults, plus pediatric populations, now faces potential demand uplift from a PMR patient population that skews over 50 and has historically been managed on extended glucocorticoid regimens. Fill-finish capacity planning and sterility assurance protocols for pre-filled syringe and autoinjector presentations will need to be stress-tested against projected PMR uptake volumes before any approval decision lands.

PMR currently has no approved advanced therapy; the disease affects an estimated population with significant steroid burden and limited alternatives, which regulators in all three jurisdictions will weigh against the REPLENISH benefit-risk profile. The EULAR 2026 simultaneous presentation adds scientific visibility that typically accelerates payer and formulary review processes downstream of approval.

The first regulatory decisions from the US, EU, and Japan submissions will serve as the measurable checkpoint for whether secukinumab's manufacturing and distribution infrastructure can absorb a new chronic-use indication at scale.

Source: Novartis via GlobeNewswire, June 3, 2026. Data simultaneously presented at the 2026 EULAR Congress.